Alkabbani, W., & Gamble, J. (2021). Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Drug Des Devel Ther.
Chicago-стиль цитированияAlkabbani, Wajd, and John-Michael Gamble. "Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date." Drug Des Devel Ther 2021.
MLA-цитированиеAlkabbani, Wajd, and John-Michael Gamble. "Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date." Drug Des Devel Ther 2021.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.